Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$13.58 -2.6%	$11.19	$3.61 ▼ $15.38	$945.48M	1.62	1.23 million shs	1.31 million shs
IMMP Prima BioMed	$1.61 -3.0%	$1.79	$1.32 ▼ $2.80	$242.43M	1.76	207,481 shs	135,546 shs
PAHC Phibro Animal Health	$23.96 -2.0%	$21.49	$16.16 ▼ $26.55	$991.05M	0.74	207,130 shs	215,002 shs
RCUS Arcus Biosciences	$8.53 -1.9%	$8.71	$6.50 ▼ $18.98	$921.20M	0.83	876,576 shs	846,882 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-2.58%	-6.92%	+6.51%	+25.05%	+213.63%
IMMP Prima BioMed	-3.01%	-12.97%	-21.08%	-15.26%	-37.35%
PAHC Phibro Animal Health	-2.00%	-1.76%	-0.70%	+9.86%	+37.07%
RCUS Arcus Biosciences	-2.25%	-6.06%	-1.91%	-5.73%	-46.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	1.152 of 5 stars	2.6	1.0	0.0	0.0	2.8	0.0	0.6
IMMP Prima BioMed	1.0737 of 5 stars	3.5	1.0	0.0	0.0	1.0	0.0	0.0
PAHC Phibro Animal Health	3.8962 of 5 stars	0.8	4.0	2.5	1.1	2.9	3.3	2.5
RCUS Arcus Biosciences	2.3764 of 5 stars	4.5	0.0	0.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	3.14	Buy	$15.00	10.46% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	334.78% Upside
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-13.19% Downside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	182.69% Upside

Current Analyst Ratings Breakdown

Latest IMMP, CRMD, PAHC, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $15.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/6/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	21.19	N/A	N/A	$1.40 per share	9.70
IMMP Prima BioMed	$5.14M	45.74	N/A	N/A	$1.05 per share	1.53
PAHC Phibro Animal Health	$1.02B	0.95	$2.07 per share	11.57	$6.34 per share	3.78
RCUS Arcus Biosciences	$258M	3.50	N/A	N/A	$5.30 per share	1.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.22	61.73	14.45	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	30.72	11.41	0.46	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest IMMP, CRMD, PAHC, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
3/25/2025	Q4 2024	CRMD CorMedix	$0.17	$0.22	+$0.05	$0.22	$27.46 million	$30.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.00%	N/A	61.54%	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Latest IMMP, CRMD, PAHC, and RCUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	4.21	3.99
IMMP Prima BioMed	N/A	18.86	N/A
PAHC Phibro Animal Health	2.67	2.91	1.23
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
IMMP Prima BioMed	2.32%
PAHC Phibro Animal Health	99.34%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
IMMP Prima BioMed	3.07%
PAHC Phibro Animal Health	50.07%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

IMMP, CRMD, PAHC, and RCUS Headlines

Recent News About These Companies

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.com

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on RCUS FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in May

June 4, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What Happened

June 4, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

June 4, 2025 | marketbeat.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.com

Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg

June 2, 2025 | thepharmaletter.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...

June 1, 2025 | gurufocus.com

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

June 1, 2025 | businesswire.com

Arcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?

May 31, 2025 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

May 30, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

May 27, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLC

May 25, 2025 | marketbeat.com

Arcus Biosciences describes new c-Kit inhibitors

May 24, 2025 | bioworld.com

Woodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

May 22, 2025 | marketbeat.com

Suvretta Capital Management LLC Has $8.58 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)

May 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP, CRMD, PAHC, and RCUS Company Descriptions

CorMedix NASDAQ:CRMD

$13.58 -0.36 (-2.58%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$13.56 -0.02 (-0.11%)

As of 06/18/2025 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Prima BioMed NASDAQ:IMMP

$1.61 -0.05 (-3.01%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.03 (+1.86%)

As of 06/18/2025 07:26 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Phibro Animal Health NASDAQ:PAHC

$23.96 -0.49 (-2.00%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$23.98 +0.02 (+0.06%)

As of 06/18/2025 04:13 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences NYSE:RCUS

$8.53 -0.17 (-1.91%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$8.52 -0.02 (-0.22%)

As of 06/18/2025 07:11 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time